Longtime WilmerHale client Thermo Fisher Scientific Inc. announced that it has signed a definitive agreement to acquire Phadia-a Sweden-based company that develops, manufactures and markets complete blood-test systems to support the clinical diagnosis and monitoring of allergy and autoimmune diseases-from European private equity firm Cinven. The deal is valued at approximately $3.5 billion in cash and is expected to be completed in the fourth quarter of 2011. Thermo Fisher, a Waltham, Massachusetts-based company, will incorporate Phadia as part of its Specialty Diagnostics business within its Analytical Technologies Segment.
Partner Hal Leibowitz, chair of WilmerHale's Corporate Group, led the team advising Thermo Fisher on the acquisition. Other members of the WilmerHale team included Partners Christian Crones, Jeffrey A. Hermanson, Tim Matthews, Lester Ross, Sven Volcker and Kenneth Zhou; Counsel Cormac O'Daly, Jerry Marr and David Morris; Senior Associates Lisa Arsenidou, Elizabeth Black, Suzy Byron, Stefan Eggert, Aileen Gao and Alison Kapilow; and Associates Philippe Claessens, Christina Frangos, Franziska Irmer, Frederik Rother and Franziska von Kummer. A press release explaining this transaction in greater detail is available on Thermo Fisher's website.